Given that we in NSCLC cells in vitro and in NSCLC patient material found a concomitant expression of Ephrin A1 and Ephrin B3, it is evident that NSCLC most likely uses another way to modulate EphA2 into a metastatic driver. The gene discussed is EFNA1; the disease is non-small cell lung carcinoma.